2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1145

The Representation of Skin Tones in Images of Patients with Lupus Erythematosus

Healthcare Disparities In Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 1130

The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 996

The Role of Flip in Differentiation and Survival of Synovial Tissue Resident Macrophages

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1095

The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1099

The Safety of Pulse Therapy- Systematic Review and Meta-analysis

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1140

The Socioeconomic, Gender, Urban-rural, and Regional Disparities in the Risk of Acute Myocardial Infarction Among RA Patients

Healthcare Disparities In Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 1155

The Status of Latin-American Women in Rheumatology

Healthcare Disparities In Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 1260

The Study of Peripheral Blood Lymphocyte Subsets and CD4+T Subsets in Recurrent Polychondritis

Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

9:00AM-11:00AM: Abstract Number: 1604

The Systemic Lupus Erythematosus Cardiovascular Risk Equation

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1261

The Time Lag – the Race in Diagnosis and Management of Hemophagocytic Lymphohistiocytosis

Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

9:00AM-11:00AM: Abstract Number: 1093

The US Prevalence of Inflammatory Bowel Disease and Associated Axial Pain: Data from the National Health & Nutrition Examination Survey (NHANES)

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1146

Therapy of Lupus Nephritis with Mycophenolate Mofetil in Routine Clinical Practice: Response Rates and Role of Ethnicity

Healthcare Disparities In Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 1042

Thy-1 (CD90) as a Novel Marker for Tracking in Vivo Skin Fibrosis

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1524

Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1428

Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort

RA – Treatments Poster II: Established Treatments

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].